1
|
Ibrahim A, Ciullo A, Li C, Garcia G, Peck K, Miyamoto K, Arumugaswami V, Marbán E. Engineered extracellular vesicles antagonize SARS-CoV-2 infection by inhibiting mTOR signaling. Biomater Biosyst 2022; 6:100042. [PMID: 35187508 PMCID: PMC8841010 DOI: 10.1016/j.bbiosy.2022.100042] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2021] [Revised: 02/11/2022] [Accepted: 02/12/2022] [Indexed: 01/19/2023] Open
Abstract
Effective treatment approaches for patients with COVID-19 remain limited and are neither curative nor widely applicable. Activated specialized tissue effector extracellular vesicles (ASTEX) derived from genetically-enhanced skin fibroblasts, exert disease-modifying bioactivity in vivo in models of heart and lung injury. Here we report that ASTEX antagonizes SARS-CoV-2 infection and its pathogenic sequelae. In human lung epithelial cells exposed to SARS-CoV-2, ASTEX is cytoprotective and antiviral. Transcriptomic analysis implicated the mammalian target of rapamycin (mTOR) pathway, as infected cells upregulated mTOR signaling and pre-exposure to ASTEX attenuated it. The implication of mTOR signaling was further confirmed using mTOR inhibition and activation, which increased and decreased viral load, respectively. Dissection of ASTEX cargo identifies miRs including miR-16 as potential inhibitors of mTOR signaling. The findings reveal a novel, dual mechanism of action for ASTEX as a therapeutic candidate for COVID-19, with synergistic antiviral and cytoprotective benefits.
Collapse
Affiliation(s)
- A.G. Ibrahim
- Smidt Heart Institute, Cedars Sinai Medical Center, Los Angeles, CA, USA
| | - A. Ciullo
- Smidt Heart Institute, Cedars Sinai Medical Center, Los Angeles, CA, USA
| | - C. Li
- Smidt Heart Institute, Cedars Sinai Medical Center, Los Angeles, CA, USA
| | - G. Garcia
- Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA
| | - K. Peck
- Smidt Heart Institute, Cedars Sinai Medical Center, Los Angeles, CA, USA
| | - K. Miyamoto
- Smidt Heart Institute, Cedars Sinai Medical Center, Los Angeles, CA, USA
| | - V. Arumugaswami
- Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA
| | - E. Marbán
- Smidt Heart Institute, Cedars Sinai Medical Center, Los Angeles, CA, USA
| |
Collapse
|
2
|
Fatima K, Masood N, Ahmad Wani Z, Meena A, Luqman S. Neomenthol prevents the proliferation of skin cancer cells by restraining tubulin polymerization and hyaluronidase activity. J Adv Res 2021; 34:93-107. [PMID: 35024183 DOI: 10.1016/j.jare.2021.06.003] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2020] [Revised: 06/07/2021] [Accepted: 06/07/2021] [Indexed: 11/28/2022] Open
Abstract
Introduction Neomenthol, a cyclic monoterpenoid, is a stereoisomer of menthol present in the essential oil of Mentha spp. It is used in food as a flavoring agent, in cosmetics and medicines because of its cooling effects. However, neomenthol has not been much explored for its anticancer potential. Additionally, targeting hyaluronidase, Cathepsin-D, and ODC by phytochemicals is amongst the efficient approach for cancer prevention and/or treatment. Objectives To investigate the molecular and cell target-based antiproliferative potential of neomenthol on human cancer (A431, PC-3, K562, A549, FaDu, MDA-MB-231, COLO-205, MCF-7, and WRL-68) and normal (HEK-293) cell lines. Methods The potency of neomenthol was evaluated on human cancer and normal cell line using SRB, NRU and MTT assays. The molecular target based study of neomenthol was carried out in cell-free and cell-based test systems. Further, the potency of neomenthol was confirmed by quantitative real-time PCR analysis and molecular docking studies. The in vivo anticancer potential of neomenthol was performed on mice EAC model and the toxicity examination was accomplished through in silico, ex vivo and in vivo approaches. Results Neomenthol exhibits a promising activity (IC50 17.3 ± 6.49 μM) against human epidermoid carcinoma (A431) cells by arresting the G2/M phase and increasing the number of sub-diploid cells. It significantly inhibits hyaluronidase activity (IC50 12.81 ± 0.01 μM) and affects the tubulin polymerization. The expression analysis and molecular docking studies support the in vitro molecular and cell target based results. Neomenthol prevents EAC tumor formation by 58.84% and inhibits hyaluronidase activity up to 10% at 75 mg/kg bw, i.p. dose. The oral dose of 1000 mg/kg bw was found safe in acute oral toxicity studies. Conclusion Neomenthol delayed the growth of skin carcinoma cells by inhibiting the tubulin polymerization and hyaluronidase activity, which are responsible for tumor growth, metastasis, and angiogenesis.
Collapse
Key Words
- AA, Arachidonic acid
- AKLP, Alkaline phosphatase
- Ab/Am, Antibiotic/antimycotic
- BE, Binding energy
- BIL, Bilirubin total & direct
- BSA, Bovine serum albumin
- BUN, Blood urea nitrogen
- CATD, Cathepsin D
- CHOL, Cholesterol
- CM-H2DCFDA, Chloromethyl derivative of dichloro fluorescin diacetate
- COX-2, Cyclooxygenase 2
- CRTN, Creatinine
- Cancer biomarker
- DCFDA, 2′,7′ dichloro fluorescin diacetate
- DFMO, α-difluoro methyl ornithine
- DHFR, Dihydrofolatereductase
- DMEM, Dulbecco’s minimal essential media
- DMSO, Dimethyl sulfoxide
- DNA, Deoxyribonucleic acid
- DOXO, Doxorubicin
- EAC, Ehlrich Ascites Carcinoma
- EC50, Half maximal effective concentration
- EDTA, Ethylene diamine tetra acetic acid
- ELISA, enzyme-linked immunosorbent assay
- Ehrlich Ascites Carcinoma
- FACS, Fluorescence-Activated Cell Sorting
- FBS, Fetal bovine serum
- FDA, Food and Drug Administration
- FOX, Ferrous oxidation-xylenol orange
- GAPDH, Glyceraldehyde 3-phosphate dehydrogenase, HEPES, N-2-hydroxyethylpiperazine-N′-2-ethanesulfonic acid
- HA, Hyaluronic acid
- HDAC, Histone deacetylase
- HDL, High density lipoprotein
- HYAL, Hyaluronidase
- Human epidermoid carcinoma
- Hyaluronidase
- IC50, Half maximal inhibitory concentration
- IDT, Integrated DNA Technologies
- Ki, Inhibitory constant
- LDH, Lactate dehydrogenase
- LOX-5, Lipoxygenase-5
- MEF, Mean erythrocyte fragility
- MMP, Mitochondrial membrane potential
- MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
- MTX, Methotrexate
- NAC, N-acetyl cysteine
- NADPH, Nicotinamide adenine dinucleotide phosphate hydrogen
- NRU, Neutral red uptake
- NaOH, Sodium hydroxide
- Neomenthol
- ODC, Ornithine decarboxylase
- OECD, Organization for Economic Co-operation and Development
- OF, Osmotic fragility
- PBS, Phosphate buffer saline
- PCR, Polymerase chain reaction
- PDB, Protein Data Bank
- PDT, Podophyllotoxin
- PEP A, pepstatin A
- PI, Propidium iodide
- PI3K, Phosphotidyl inositol-3 kinase
- PKB/Akt, Protein kinase B
- RBC, Red blood cell
- RIPA, Radio immune precipitation assay buffer
- RNA, Ribonucleic acid
- RNase A, Ribonuclease A
- ROS, Reactive oxygen species
- RPMI, Roswell park memorial institute
- Rh123, Rhodamine 123
- SGOT, Aspartate aminotransferase
- SGPT, Alanine aminotransferase
- SRB, Sulphorhodamine B
- TCA, Tricarboxylic acid
- TMPD, N,N,N′,N′-tetramethyl-p-phenylenediamine
- TNBS, Trinitrobenzenesulphonic acid
- TPA, 12-O-Tetradecanoylphorbol-13-acetate
- TPR, Total protein
- TRIG, Triglyceraldehyde
- TRPM8, Transient receptor potential member 8
- Tubulin
- URIC, Uric acid
- WBC, White blood cell
- mTOR, Mammalian target of rapamycin
Collapse
|
3
|
Liang C, Hui N, Liu Y, Qiao G, Li J, Tian L, Ju X, Jia M, Liu H, Cao W, Yu P, Li H, Ren X. Insights into forsythia honeysuckle (Lianhuaqingwen) capsules: A Chinese herbal medicine repurposed for COVID-19 pandemic. Phytomed Plus 2021; 1:100027. [PMID: 35399819 PMCID: PMC7833308 DOI: 10.1016/j.phyplu.2021.100027] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/20/2020] [Revised: 01/08/2021] [Accepted: 01/11/2021] [Indexed: 04/17/2023]
Abstract
Background In December 2019, a novel coronavirus, SARS-CoV-2 caused a series of acute atypical respiratory diseases worldwide. However, there is still a lack of drugs with clear curative effects, and the clinical trial research of vaccines has not been completely finished. Purpose LH capsules are approved TCM patent medicine that are widely used for the treatment of respiratory tract infectious diseases caused by colds and flu. On April 12, 2020, LH capsules and granules were officially repurposed by the China Food and Drug Administration (CFDA) for patients with mild COVID-19 based on their safety and efficacy demonstrated through multicentre, randomized, controlled clinical trials. We hope to conduct a comprehensive review of it through modern pharmacy methods, and try to explain its possible mechanism. Methods Using the full names of LH capsules Lianhuaqingwen, Lianhua Qingwen andSARS-COV-2, COVID-19 as the keywords of the search terms, systemically search for existing related papers in various databases such as Web of Science and PubMed. And completed the collection of clinical data in ClinicalTrials.gov and Chinese Clinical Trial Registry. Last but not least, we have sorted out the anti-inflammatory and antiviral mechanisms of LH capsules through literature and Selleck. Results This review systematically sorted out the active ingredients in LH capsules. Furthermore, the related pharmacological and clinical trials of LH capsule on SARS-CoV-2, IAV and IBV were discussed in detail. Moreover, the present review provides the first summary of the potential molecular mechanism of specific substances in LH capsules involved in resistance to SARS-COV-2 infection and the inhibition of cytokine storm syndrome (CSS) caused by IL-6. Conclusion This review summarizes the available reports and evidence that support the use of LH capsules as potential drug candidates for the prevention and treatment of COVID-19. However, TCM exerts its effects through multiple targets and multiple pathways, and LH capsules are not an exception. Therefore, the relevant mechanisms need to be further improved and experimentally verified.
Collapse
Key Words
- 3C-like protease (3CLpro)
- 3CLpro, 3C-like protease
- ACE2, Angiotensin-converting enzyme 2
- AECOPD, Acute exacerbation of chronic obstructive pulmonary disease
- AIDS, Acquired immune deficiency syndrome
- AQP3, Aquaporins 3
- ARDS, Acute respiratory distress syndrome
- CAT, COPD assessment test
- CC50, 50% Cytotoxic concentration
- CCL-2/MCP-1, C—C motif ligand 2/monocyte chemoattractant protein-1
- CFDA, China Food and Drug Administration
- COPD, Chronic obstructive pulmonary disease
- COVID-19
- COVID-19, Coronavirus disease 2019
- CPE, Cytopathic effect
- CSS, Cytokine storm syndrome
- CT, Computed tomography
- CXCL-10/IP-10, C-X-C Motif Chemokine Ligand 10/ Interferon Gamma-induced Protein 10
- Cytokine storm syndrome (CSS)
- DMSO, Dimethyl sulfoxide
- E protein, Envelope protein
- ERK, Extracellular signal-regulated kinase
- FBS, Fatal bovine serum
- Forsythia honeysuckle (Lianhuaqingwen,LH) capsules
- Grb2, Growth factor receptor-bound protein 2
- HIV, Human immunodeficiency virus
- HPLC, High-performance liquid chromatography
- HSV-1, Herpes simplex virus type 1
- HVJ, Hemagglutinating virus of Japan
- Hep-2, Human epithelial type 2
- Huh-7, Human Hepatocellular Carcinoma-7
- IAV, Influenza A virus
- IBV, Influenza B virus
- IC50, 50% Inhibition concentration
- IFN-λ1, Interferon-λ1
- IL-6, Interleukin-6
- IL-6R, IL-6 Receptor
- IL-8, Interleukin-8
- IP-10, Interferon-inducible protein-10
- JAK/STAT, Janus kinase/signal transducers and activators of transcription
- JAK1/2, Janus kinase1/2
- LD50, 50% Lethal dose
- LH capsules, Forsythia honeysuckle (Lianhuaqingwen) capsules
- M protein, Membrane protein
- MAPK, Mitogen-activated protein kinase
- MCP-1, Monocyte chemotactic protein 1
- MDCK, Madin-darby canine kidney
- MEK, Mitogen-activated protein kinase kinase
- MERS, Middle east respiratory syndrome
- MIP-1β, Macrophage Inflammatory Protein-1β
- MLD50, 50% Minimum lethal dose
- MOF, Multifunctional organ damage
- MOI, Multiplicity of infection
- MTT, Methyl Thiazolyl Tetrazolium
- NF-kB, Nuclear transcription factor kappa-B
- NHC, National Health Commission
- ORFs, Open reading frames
- PBS, Phosphate buffered saline
- PHN, Phillyrin
- PI3K, Phosphoinositide 3-kinases
- PKA/p-CREB, Protein kinase A /phosphorylated cAMP response element-binding protein
- PKB, Akt, Protein kinase B
- PLpro, Papain-like proteases
- PRC, People's Republic of China
- QC, Quality control
- RANTES, Regulated on activation normal T cell expressed and secreted
- RSV, Respiratory syncytial virus
- RT-PCR, Reverse transcription PCR
- Ras, Ras GTPase
- SARS-CoV-2
- TCID50, 50% Tissue culture infective dose
- TD0, Non-toxic Dose
- TD50, Half-toxic dose
- Vero E6, African Green Monkey Kidney Epithelial-6
- gp-130, Glycoprotein 130
- mIL-6R, Membrane-bound form IL-6 Receptor
- mTOR, Mammalian target of rapamycin
- nsps, Non-structural proteins
- qPCR, Quantitative PCR
Collapse
Affiliation(s)
- Chengyuan Liang
- Faculty of Pharmacy, Shaanxi University of Science & Technology, Xi'an 710021, PR China
| | - Nan Hui
- Faculty of Pharmacy, Shaanxi University of Science & Technology, Xi'an 710021, PR China
| | - Yuzhi Liu
- Faculty of Pharmacy, Shaanxi University of Science & Technology, Xi'an 710021, PR China
| | - Guaiping Qiao
- Faculty of Pharmacy, Shaanxi University of Science & Technology, Xi'an 710021, PR China
| | - Juan Li
- Faculty of Pharmacy, Shaanxi University of Science & Technology, Xi'an 710021, PR China
| | - Lei Tian
- Faculty of Pharmacy, Shaanxi University of Science & Technology, Xi'an 710021, PR China
| | - Xingke Ju
- Faculty of Pharmacy, Shaanxi University of Science & Technology, Xi'an 710021, PR China
| | - Minyi Jia
- Faculty of Pharmacy, Shaanxi University of Science & Technology, Xi'an 710021, PR China
| | - Hong Liu
- Zhuhai Jinan Selenium Source Nanotechnology Co., Ltd., Hengqin New Area, Zhuhai 519030, PR China
| | - Wenqiang Cao
- Zhuhai Jinan Selenium Source Nanotechnology Co., Ltd., Hengqin New Area, Zhuhai 519030, PR China
| | - Pengcheng Yu
- School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 210009, PR China
| | - Han Li
- Faculty of Pharmacy, Shaanxi University of Science & Technology, Xi'an 710021, PR China
| | - Xiaodong Ren
- Medical College, Guizhou University, Guiyang 550025, PR China
| |
Collapse
|
4
|
Kaushik V, Singh A, Arya A, Sindhu SC, Sindhu A, Singh A. Enhanced production of cordycepin in Ophiocordyceps sinensis using growth supplements under submerged conditions. Biotechnol Rep (Amst) 2020; 28:e00557. [PMID: 33294405 PMCID: PMC7691154 DOI: 10.1016/j.btre.2020.e00557] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/12/2020] [Revised: 10/24/2020] [Accepted: 11/09/2020] [Indexed: 11/23/2022]
Abstract
Cordycepin is a crucial bioactive compound produced by the fungus Cordyceps spp. Its therapeutic potential has been recognized for a wide range of biological properties such as anticancer, anti-diabetic, antidepressant, antioxidant, immunomodulation, etc. Moreover, its human random clinical trials depicted a promising anti-inflammatory activity that reduced the airway inflammation remarkably in asthmatic patients. But its overexploitation and low production of cordycepin in naturally growing biomass are insufficient to meet its existing market demand for its therapeutic use. Therefore, strategies for enhancement of cordycepin production in Cordyceps spp. are warranted. However, specifically, wild type Ophiocordyceps sinensis possesses a very low content of cordycepin and has restricted growth in natural mycelial biomass. To overcome these limitations, this study attempted to enhance cordycepin production in its mycelial biomass in vitro under submerged conditions by adding various growth supplements. The effect of these growth supplements was evaluated by reversed-phase high-performance liquid chromatography (RP-HPLC) which demonstrated that among nucleosides- hypoxanthine and adenosine; amino acids-glycine and glutamine; plant hormones- 1-naphthaleneacetic acid (NAA) and 3-indoleacetic acid (IAA); vitamin-thiamine (B1) from each group of growth supplements yielded a higher amount of cordycepin with 466.48 ± 3.88, 380.23 ± 1.78, 434.97 ± 2.32, 269.78 ± 2.92, 227.61 ± 2.34, 226.02 ± 1.69 and 185.26 ± 2.35 mg/L respectively as compared to control with 13.66 ± 0.64 mg/L. Further, at the transcriptional level, quantitative real time-polymerase chain reaction (qRT-PCR) analysis of genes associated with metabolism and cordycepin biosynthesis depicted significant upregulation of major downstream genes- NT5E, RNR, purA, and ADEK which corroborated well with RP-HPLC analysis. Taken together, the present study identified growth supplements as potential precursors to activate the cordycepin biosynthesis pathway leading to improved cordycepin production in O. sinensis.
Collapse
Key Words
- ANOVA, Analysis of Variance
- Cordycepin biosynthesis pathway
- Cordycepin production
- Growth supplements
- KH2PO4, Potassium dihydrogen phosphate
- Medicinal mushroom
- MgSO4, Magnesium sulfate
- Mycelial biomass
- RP-HPLC, Reversed-phase high-performance liquid chromatography
- SDA, Sabouraud dextrose agar
- SEM, Standard error mean
- cDNA, Complementary deoxyribonucleic acid
- dNTP, Deoxyribonucleotide triphosphate
- mRNA, Messenger ribonucleic acid
- mTOR, Mammalian target of rapamycin
- qRT-PCR, Quantitative reverse transcriptase-polymerase chain reaction
Collapse
Affiliation(s)
- Vikas Kaushik
- Department of Biotechnology, Deenbandhu Chhotu Ram University of Science and Technology, Murthal, 131039, Sonepat, Haryana, India
| | - Amanvir Singh
- Department of Chemistry, Deenbandhu Chhotu Ram University of Science and Technology, Murthal, 131039, Sonepat, Haryana, India
| | - Aditi Arya
- Department of Biotechnology, Deenbandhu Chhotu Ram University of Science and Technology, Murthal, 131039, Sonepat, Haryana, India
| | - Sangeeta Chahal Sindhu
- Department of Foods and Nutrition, Chaudhary Charan Singh Haryana Agricultural University, Hisar, 125004, Haryana, India
| | - Anil Sindhu
- Department of Biotechnology, Deenbandhu Chhotu Ram University of Science and Technology, Murthal, 131039, Sonepat, Haryana, India
| | - Ajay Singh
- Haryana Agro Industries Corporation, Research and Development Centre, Murthal, 131039, Sonepat, Haryana, India
| |
Collapse
|
5
|
Tiwari A, Saigal S, Choudhary NS, Saha S, Rastogi A, Bhangui P, Saraf N, Srinivasan T, Yadav SK, Gautam D, Nundy S, Soin AS. De Novo Malignancy After Living Donor Liver Transplantation: A Large Volume Experience. J Clin Exp Hepatol 2020; 10:448-452. [PMID: 33029053 PMCID: PMC7527845 DOI: 10.1016/j.jceh.2020.02.001] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/11/2019] [Accepted: 02/09/2020] [Indexed: 12/12/2022] Open
Abstract
BACKGROUND AND AIMS Liver transplantation (LT) recipients such as all organ transplant recipients, have a risk of developing de novo malignancies owing to prolonged immunosuppression. However, there is limited data on this after living donor liver transplantation (LDLT), wherein immunosuppression levels are less than in deceased donor transplantation. We aim to describe experience of de novo malignancies from a predominantly LDLT center. MATERIALS AND METHODS A total of 2100 adults (age >18 years) who underwent LT between January 2006 and December 2017 were retrospectively analyzed from a prospectively collected database. The data were analyzed up to June 2019. Data are shown as number, percentage, mean ± standard deviation, and median (interquartile range). RESULTS Of 2100 patients who underwent LDLT, 21 (1%) patients developed de novo malignancy after transplantation. The de novo malignancy cohort comprised 20 males and 1 female, aged 50 ± 8.8 years. The distribution of de novo malignancies was as follows: 7 oropharyngeal (carcinoma of buccal and oral mucosa), 4 lung, 2 squamous cell carcinoma of skin, 2 lymphoma, 1 each of brain, colonic, gastric; ovary, pancreatic, and prostate. These malignancies were diagnosed at a median follow-up of 42 months (32-73) after LT. Over a median follow-up of 38 months (10-56) after the diagnosis of de novo malignancy, 6 patients (28.5%) died. Patients with de novo malignancy had a higher follow-up after LDLT, 94.3 ± 32.9 versus 62.5 ± 41.8 months, P = 0.000. Patients with alcohol as etiology for LT had higher trend of de novo malignancies (33.3% versus 26.4%), P = 0.46. CONCLUSION The incidence of de novo malignancy was 1% at a median follow-up of 42 (32-73) months. De novo malignancies following LDLT, although uncommon, are associated with significant mortality. A careful screening protocol should be followed after transplantation for early detection of de novo malignancies.
Collapse
Affiliation(s)
- Anisha Tiwari
- Institute of Liver Transplantation and Regenerative Medicine, Medanta The Medicity, Gurugram, India
| | - Sanjiv Saigal
- Institute of Liver Transplantation and Regenerative Medicine, Medanta The Medicity, Gurugram, India,Address for correspondence. Dr Sanjiv Saigal MD, DM, MRCP, Director Hepatology and Liver Transplantation, Institute of Liver Transplantation and Regenerative Medicine, Medanta The Medicity, Sector 38, Gurgaon, Haryana, 122001, India.
| | - Narendra S. Choudhary
- Institute of Liver Transplantation and Regenerative Medicine, Medanta The Medicity, Gurugram, India
| | - Sujeet Saha
- Institute of Liver Transplantation and Regenerative Medicine, Medanta The Medicity, Gurugram, India
| | - Amit Rastogi
- Institute of Liver Transplantation and Regenerative Medicine, Medanta The Medicity, Gurugram, India
| | - Prashant Bhangui
- Institute of Liver Transplantation and Regenerative Medicine, Medanta The Medicity, Gurugram, India
| | - Neeraj Saraf
- Institute of Liver Transplantation and Regenerative Medicine, Medanta The Medicity, Gurugram, India
| | - Thiagrajan Srinivasan
- Institute of Liver Transplantation and Regenerative Medicine, Medanta The Medicity, Gurugram, India
| | - Sanjay K. Yadav
- Institute of Liver Transplantation and Regenerative Medicine, Medanta The Medicity, Gurugram, India
| | - Dheeraj Gautam
- Department of Histopathology, Medanta The Medicity, Gurugram, India
| | - Samiran Nundy
- Department of Surgical Gastroenterology and Liver Transplantation, Sir Ganga Ram Hospital, New Delhi, India
| | - Arvinder S. Soin
- Institute of Liver Transplantation and Regenerative Medicine, Medanta The Medicity, Gurugram, India
| |
Collapse
|
6
|
Addie RD, de Jong Y, Alberti G, Kruisselbrink AB, Que I, Baelde H, Bovée JVMG. Exploration of the chondrosarcoma metabolome; the mTOR pathway as an important pro-survival pathway. J Bone Oncol 2019; 15:100222. [PMID: 30766792 PMCID: PMC6360255 DOI: 10.1016/j.jbo.2019.100222] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2018] [Revised: 01/27/2019] [Accepted: 01/28/2019] [Indexed: 12/18/2022] Open
Abstract
Background Chondrosarcomas are malignant cartilage-producing tumors showing mutations and changes in gene expression in metabolism related genes. In this study, we aimed to explore the metabolome and identify targetable metabolic vulnerabilities in chondrosarcoma. Methods A custom-designed metabolic compound screen containing 39 compounds targeting different metabolic pathways was performed in chondrosarcoma cell lines JJ012, SW1353 and CH2879. Based on the anti-proliferative activity, six compounds were selected for validation using real-time metabolic profiling. Two selected compounds (rapamycin and sapanisertib) were further explored for their effect on viability, apoptosis and metabolic dependency, in normoxia and hypoxia. In vivo efficacy of sapanisertib was tested in a chondrosarcoma orthotopic xenograft mouse model. Results Inhibitors of glutamine, glutathione, NAD synthesis and mTOR were effective in chondrosarcoma cells. Of the six compounds that were validated on the metabolic level, mTOR inhibitors rapamycin and sapanisertib showed the most consistent decrease in oxidative and glycolytic parameters. Chondrosarcoma cells were sensitive to mTORC1 inhibition using rapamycin. Inhibition of mTORC1 and mTORC2 using sapanisertib resulted in a dose-dependent decrease in viability in all chondrosarcoma cell lines. In addition, induction of apoptosis was observed in CH2879 after 24 h. Treatment of chondrosarcoma xenografts with sapanisertib slowed down tumor growth compared to control mice. Conclusions mTOR inhibition leads to a reduction of oxidative and glycolytic metabolism and decreased proliferation in chondrosarcoma cell lines. Although further research is needed, these findings suggest that mTOR inhibition might be a potential therapeutic option for patients with chondrosarcoma.
Collapse
Key Words
- ACT, Atypical cartilaginous tumor
- BLI, Bioluminescence imaging
- BSA, Bovine serum albumin
- BSO, Buthionine sulfoximine
- Chondrosarcoma
- D2HG, d-2-Hydroxyglutarate
- DMSO, Dimethyl sulfoxide
- ECAR, Extracellular acidification rate
- FBS, Fetal bovine serum
- FCCP, Carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone
- FLI, Fluorescence imaging
- HIF, Hypoxia-inducible factor
- IDH, Isocitrate dehydrogenase
- Metabolism
- OCR, Oxygen consumption rate
- ROS, Reactive oxygen species
- Rapamycin
- mCT, Micro computed tomography
- mTOR, Mammalian target of rapamycin
- mTOR, Sapanisertib
- α-KG, α-ketoglutarate
Collapse
Affiliation(s)
- Ruben D Addie
- Department of Pathology, Leiden University Medical Centre, Leiden, the Netherlands
| | - Yvonne de Jong
- Department of Pathology, Leiden University Medical Centre, Leiden, the Netherlands
| | - Gaia Alberti
- Department of Pathology, Leiden University Medical Centre, Leiden, the Netherlands
| | | | - Ivo Que
- Department of Radiology, Leiden University Medical Centre, Leiden, the Netherlands
| | - Hans Baelde
- Department of Pathology, Leiden University Medical Centre, Leiden, the Netherlands
| | - Judith V M G Bovée
- Department of Pathology, Leiden University Medical Centre, Leiden, the Netherlands
| |
Collapse
|
7
|
Hosoya M, Saeki T, Saegusa C, Matsunaga T, Okano H, Fujioka M, Ogawa K. Estimating the concentration of therapeutic range using disease-specific iPS cells: Low-dose rapamycin therapy for Pendred syndrome. Regen Ther 2018; 10:54-63. [PMID: 30581897 PMCID: PMC6299162 DOI: 10.1016/j.reth.2018.11.001] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2018] [Revised: 10/28/2018] [Accepted: 11/12/2018] [Indexed: 01/31/2023] Open
Abstract
Introduction Pendred syndrome is an autosomal-recessive disease characterized by congenital hearing loss and thyroid goiter. Previously, cell stress susceptibilities were shown to increase in patient-derived cells with intracellular aggregation using an in vitro acute cochlear cell model derived from patient-specific pluripotent stem (iPS) cells. Moreover, we showed that rapamycin can relieve cell death. However, studies regarding long-term cell survival without cell stressors that mimic the natural course of disease or the rational minimum concentration of rapamycin that prevents cell death are missing. Methods In this report, we first investigated the rational minimum concentration of rapamycin using patient-specific iPS cells derived-cochlear cells with three different conditions of acute stress. We next confirmed the effects of rapamycin in long-term cell survival and phenotypes by using cochlear cells derived from three different patient-derived iPS cells. Results We found that inner ear cells derived from Pendred syndrome patients are more vulnerable than those from healthy individuals during long-term culturing; however, this susceptibility was relieved via treatment with low-dose rapamycin. The slow progression of hearing loss in patients may be explained, in part, by the vulnerability observed in patient cells during long-term culturing. We successfully evaluated the rational minimum concentration of rapamycin for treatment of Pendred syndrome. Conclusion Our results suggest that low-dose rapamycin not only decreases acute symptoms but may prevent progression of hearing loss in Pendred syndrome patients. In vitro chronic disorder model of Pendred syndrome is established. The vulnerability observed during long-term culturing explains progression of PDS. Low-dose rapamycin relief the cell vulnerability observed in PDS patients. PDS iPSCs reveal a rational treatment strategy for chronic progressive hearing loss.
Collapse
Affiliation(s)
- Makoto Hosoya
- Department of Otorhinolaryngology, Head and Neck Surgery, Keio University School of Medicine, 35 Shinanomachi Shinjuku-ku, Tokyo 160-8582, Japan
| | - Tsubasa Saeki
- Department of Physiology, Keio University School of Medicine, 35 Shinanomachi Shinjuku-ku, Tokyo 160-8582, Japan
| | - Chika Saegusa
- Department of Otorhinolaryngology, Head and Neck Surgery, Keio University School of Medicine, 35 Shinanomachi Shinjuku-ku, Tokyo 160-8582, Japan
| | - Tatsuo Matsunaga
- The Laboratory of Auditory Disorders and Division of Hearing and Balance Research, National Institute of Sensory Organs, National Tokyo Medical Center, 2-5-1 Higashigaoka, Meguro-ku, Tokyo 152-8902, Japan.,Medical Genetics Center, National Tokyo Medical Center, 2-5-1 Higashigaoka, Meguro-ku, Tokyo 152-8902, Japan
| | - Hideyuki Okano
- Department of Physiology, Keio University School of Medicine, 35 Shinanomachi Shinjuku-ku, Tokyo 160-8582, Japan
| | - Masato Fujioka
- Department of Otorhinolaryngology, Head and Neck Surgery, Keio University School of Medicine, 35 Shinanomachi Shinjuku-ku, Tokyo 160-8582, Japan
| | - Kaoru Ogawa
- Department of Otorhinolaryngology, Head and Neck Surgery, Keio University School of Medicine, 35 Shinanomachi Shinjuku-ku, Tokyo 160-8582, Japan
| |
Collapse
|
8
|
Chand S, McKnight AJ, Shabir S, Chan W, McCaughan JA, Maxwell AP, Harper L, Borrows R. Analysis of single nucleotide polymorphisms implicate mTOR signalling in the development of new-onset diabetes after transplantation. BBA Clin 2016; 5:41-5. [PMID: 27051588 PMCID: PMC4802392 DOI: 10.1016/j.bbacli.2015.12.004] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/21/2015] [Revised: 12/07/2015] [Accepted: 12/17/2015] [Indexed: 12/13/2022]
Abstract
Introduction Despite excellent first year outcomes in kidney transplantation, there remain significant long-term complications related to new-onset diabetes after transplantation (NODAT). The purpose of this study was to validate the findings of previous investigations of candidate gene variants in patients undergoing a protocolised, contemporary immunosuppression regimen, using detailed serial biochemical testing to identify NODAT development. Methods One hundred twelve live and deceased donor renal transplant recipients were prospectively followed-up for NODAT onset, biochemical testing at days 7, 90, and 365 after transplantation. Sixty-eight patients were included after exclusion for non-white ethnicity and pre-transplant diabetes. Literature review to identify candidate gene variants was undertaken as described previously. Results Over 25% of patients developed NODAT. In an adjusted model for age, sex, BMI, and BMI change over 12 months, five out of the studied 37 single nucleotide polymorphisms (SNPs) were significantly associated with NODAT: rs16936667:PRDM14 OR 10.57;95% CI 1.8–63.0;p = 0.01, rs1801282:PPARG OR 8.5; 95% CI 1.4–52.7; p = 0.02, rs8192678:PPARGC1A OR 0.26; 95% CI 0.08–0.91; p = 0.03, rs2144908:HNF4A OR 7.0; 95% CI 1.1–45.0;p = 0.04 and rs2340721:ATF6 OR 0.21; 95%CI 0.04–1.0; p = 0.05. Conclusion This study represents a replication study of candidate SNPs associated with developing NODAT and implicates mTOR as the central regulator via altered insulin sensitivity, pancreatic β cell, and mitochondrial survival and dysfunction as evidenced by the five SNPs. General significance Highlights the importance of careful biochemical phenotyping with oral glucose tolerance tests to diagnose NODAT in reducing time to diagnosis and missed cases. This alters potential genotype:phenotype association. The replication study generates the hypothesis that mTOR signalling pathway may be involved in NODAT development.
Oral glucose tolerance tests reduce time to NODAT diagnosis and missed cases Biochemical testing changes genotype:phenotype association mTOR signalling pathway may be involved in NODAT development
Collapse
Key Words
- ATF6, Activated transcription factor
- BMI, Body mass index
- GWAS, Genome-wide association study
- HLA, Human leucocyte antigen
- HNF4, Hepatocyte nuclear factor 4
- NODAT, New-onset diabetes after transplantation
- New-onset diabetes after transplantation
- PI3, Phospho-inositide 3-kinase
- PPARGC1α, Peroxisome proliferator-activated receptor gamma co-activator 1 alpha
- PPARy, Peroxisome proliferator-activated receptor gamma
- PRDM14, PR domain zinc protein 14
- SNP, Single nucleotide polymorphism
- mTOR
- mTOR, Mammalian target of rapamycin
- single nucleotide polymorphisms
Collapse
Affiliation(s)
- S Chand
- Department of Nephrology and Kidney Transplantation, Queen Elizabeth Hospital, Birmingham B15 2WB, United Kingdom; Centre for Translational Inflammation Research, University of Birmingham, Birmingham B15 2WB, United Kingdom
| | - A J McKnight
- Regional Nephrology Unit, Belfast City Hospital, Belfast BT9 7AB, Northern Ireland
| | - S Shabir
- Department of Nephrology and Kidney Transplantation, Queen Elizabeth Hospital, Birmingham B15 2WB, United Kingdom; Centre for Translational Inflammation Research, University of Birmingham, Birmingham B15 2WB, United Kingdom
| | - W Chan
- Department of Nephrology and Kidney Transplantation, Queen Elizabeth Hospital, Birmingham B15 2WB, United Kingdom
| | - J A McCaughan
- Regional Nephrology Unit, Belfast City Hospital, Belfast BT9 7AB, Northern Ireland
| | - A P Maxwell
- Regional Nephrology Unit, Belfast City Hospital, Belfast BT9 7AB, Northern Ireland
| | - L Harper
- Department of Nephrology and Kidney Transplantation, Queen Elizabeth Hospital, Birmingham B15 2WB, United Kingdom; Centre for Translational Inflammation Research, University of Birmingham, Birmingham B15 2WB, United Kingdom
| | - R Borrows
- Department of Nephrology and Kidney Transplantation, Queen Elizabeth Hospital, Birmingham B15 2WB, United Kingdom; Centre for Translational Inflammation Research, University of Birmingham, Birmingham B15 2WB, United Kingdom
| |
Collapse
|
9
|
Abstract
Despite a major improvement in the treatment of advanced kidney cancer by the recent introduction of targeted agents such as multi-kinase inhibitors, long-term benefits are still limited and a significant unmet medical need remains for this disease. Cancer immunotherapy has shown its potential by the induction of long-lasting responses in a small subset of patients, however, the unspecific immune interventions with (high dose) cytokines used so far are associated with significant side effects. Specific cancer immunotherapy may circumvent these problems by attacking tumor cells while sparing normal tissue with the use of multi-peptide vaccination being one of the most promising strategies. We here summarize the clinical and translational data from phase I and II trials investigating IMA901. Significant associations of clinical benefit with detectable T cell responses against the IMA901 peptides and encouraging survival data in treated patients has prompted the start of a randomized, controlled phase III trial in 1st line advanced RCC with survival results expected toward the end of 2015. Potential combination strategies with the recently discovered so-called checkpoint inhibitors are also discussed.
Collapse
Key Words
- 5-FU, 5 fluorouracil
- AE, Adverse event
- CTL, Cytotoxic T-lymphocyte
- CY, Cyclophosphamide
- Cancer vaccine
- DC, Dendritic cell
- DCR, Disease control rate
- ECG, Electrocardiogram
- ELISpot, Enzyme-linked immunospot assay
- FDA, Food and Drug Administration
- GM-CSF
- HBV, Hepatitis B virus
- HLA, Human leukocyte antigen
- IFN, Interferon
- IL, Interleukin
- IMA901
- MDSC, Myeloid-derived suppressor cells
- MHC, Major histocompatibility complex
- MSKCC, Memorial Sloan Kettering Cancer Center
- NCI-CTC, National Cancer Institute-Common Toxicity Criteria
- OS, Overall survival
- PD, Progressive disease
- PFS, Progression-free survival
- PK, Pharmacokinetic
- PR, Partial response
- RCC, Renal cell carcinoma
- RECIST, Response Evaluation Criteria in Solid Tumors
- SAE, Serious adverse event
- SD, Stable disease
- TKI, Tyrosine-kinase inhibitors
- TNF, Tumor necrosis factor
- TUMAP, Tumor-associated peptides
- Tregs, Regulatory T-cells
- VEGF, Vascular endothelial growth factor
- ccRCC, Clear cell renal cell carcinoma
- checkpoint inhibitor
- cyclophosphamide
- i.d., intradermal
- immunotherapy
- intradermally
- kidney cancer
- mRNA, Messenger ribonucleic acid
- mTOR, Mammalian target of rapamycin
- mg, Milligram
- n, Number
- renal cell carcinoma
- s.c., subcutaneous, subcutaneously
- tumor-associated peptides
- vaccination
- μg, Microgram
Collapse
|
10
|
Golovine K, Makhov P, Naito S, Raiyani H, Tomaszewski J, Mehrazin R, Tulin A, Kutikov A, Uzzo RG, Kolenko VM. Piperlongumine and its analogs down-regulate expression of c-Met in renal cell carcinoma. Cancer Biol Ther 2015; 16:743-9. [PMID: 25801713 PMCID: PMC4623021 DOI: 10.1080/15384047.2015.1026511] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2015] [Accepted: 03/01/2015] [Indexed: 12/29/2022] Open
Abstract
The c-Met protein, a transmembrane receptor tyrosine kinase, is the product of a proto-oncogene. Its only known ligand, hepatocyte growth factor (HGF), regulates cell growth, motility, migration, invasion, proliferation, and angiogenesis. The aberrant expression of c-Met is often associated with poor prognosis in multiple cancers, including renal cell carcinoma (RCC). Silencing or inactivation of c-Met leads to decreased viability of cancer cells, thereby making ablation of c-Met signaling an attractive concept for developing novel strategies for the treatment of renal tumors. Naturally-occurring products or substances are the most consistent source of drug development. As such, we investigated the functional impact of piperlongumine (PL), a naturally occurring alkaloid present in the Long pepper (Piper longum) on c-Met expression in RCC cells and demonstrated that PL and its analogs rapidly reduce c-Met protein and RNA levels in RCC cells via ROS-dependent mechanism. PL-mediated c-Met depletion coincided with the inhibition of downstream c-Met signaling; namely Erk/MAPK, STAT3, NF-κB and Akt/mTOR. As such, PL and PL analogs hold promise as potential therapeutic agents for the treatment of metastatic RCC and the prevention of postoperative RCC recurrence.
Collapse
Key Words
- Erk, Extracellular signal-regulated kinase
- FAK, Focal adhesion kinase
- HGF, Hepatocyte growth factor
- MAPK, Mitogen-activated protein kinase
- NF-kB, Nuclear factor kappaB
- PL, Piperlongumine
- PL-Di, PL-Dimer
- PL-FPh, PL-fluorophenyl
- RCC, Renal cell carcinoma
- RECIST, Response evaluation criteria in solid tumors
- RNA, Ribonucleic acid
- ROS
- ROS, Reactive oxygen species
- STAT, Signal transducer and activator of transcription
- TKIs, Tyrosine kinase inhibitors
- VEGFR, Vascular endothelial growth factor receptor
- c-Met
- cancer
- mTOR, Mammalian target of rapamycin
- piperlongumine
- renal
Collapse
Affiliation(s)
| | - Peter Makhov
- Cancer Biology Program; Fox Chase Cancer Center; Philadelphia, PA, USA
| | - Sei Naito
- Cancer Biology Program; Fox Chase Cancer Center; Philadelphia, PA, USA
| | - Henish Raiyani
- Cancer Biology Program; Fox Chase Cancer Center; Philadelphia, PA, USA
| | - Jeffrey Tomaszewski
- Division of Urologic Oncology; Department of Surgery; Fox Chase Cancer Center; Philadelphia, PA, USA
| | - Reza Mehrazin
- Division of Urologic Oncology; Department of Surgery; Fox Chase Cancer Center; Philadelphia, PA, USA
| | - Alexei Tulin
- Cancer Epigenetics Program; Fox Chase Cancer Center; Philadelphia, PA, USA
| | - Alexander Kutikov
- Division of Urologic Oncology; Department of Surgery; Fox Chase Cancer Center; Philadelphia, PA, USA
| | - Robert G Uzzo
- Division of Urologic Oncology; Department of Surgery; Fox Chase Cancer Center; Philadelphia, PA, USA
| | | |
Collapse
|